CEO SUMMARY: Bringing a new proprietary diagnostic test to market is an arduous process. It takes patience and planning to complete the journey from test development to payer reimbursement. This slow process stems from the fact that the healthcare reimbursement system is fragmented, with the three main segments being Medicare, Medicaid, and private payers, each […]
- IVD, Diagnostics and Informatics Update
Coverage, Reimbursement Still Difficult for New Lab Tests
When considering new tests, health insurers want adequate data on test accuracy and clinical value
- By Robert Michel
- > From the Volume XXIX, No. 11 - August 8, 2022 Issue
- Tags: Aetna, AIM Specialty Health, AMA, American Medical Association, Anthem, avalon healthcare solutions, Blue Cross Blue Shield, Cigna, clfs, Clinical Laboratory Fee Schedule, Concert Genetics, CPT® codes, crosswalk, current procedural terminology, ECRI, Elevance Health, eviCore Healthcare, Executive War College Conference on Laboratory and Pathology Management, gapfill, in vitro diagnostics, InformedDNA, IVD, ivd/lab informatics, Medicaid, Medicaid HMO, Medicare Advantage, Medicare Part B, Rob Metcalf, Shipwright Healthcare Group, Steve Stonecypher, UnitedHealthcare
